Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy

Trends in Cancer

Volumn 3, Issue 8, 2017, Pages 583-592

  Wang, Haiping ^a,b   Franco, Fabien ^a,b   Ho, Ping Chih ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Ludwig Lausanne Branch   (Switzerland)

Author keywords

cancer immunology; immunometabolism; immunosuppressive; regulatory T cell; tumor microenvironment

Indexed keywords

CANCER IMMUNOTHERAPY; CELL FUNCTION; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNOMODULATION; LEUKOCYTE METABOLISM; MALIGNANT NEOPLASM; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; AUTOIMMUNITY; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASM; PROCEDURES; SIGNAL TRANSDUCTION; TRENDS; TUMOR ESCAPE;

IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85024120151     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2017.06.005     Document Type: Review

References (89)

1. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
2. Baitsch, L., et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J. Clin. Invest. 121 (2011), 2350–2360.
3. Wherry, E.J., T cell exhaustion. Nat. Immunol. 12 (2011), 492–499.
4. Kuang, D.M., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J. Exp. Med. 206 (2009), 1327–1337.
5. Engelhardt, J.J., et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
6. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174.
7. Vignali, D.A.A., et al. How regulatory T cells work. Nat. Rev. Immunol. 8 (2008), 523–532.
8. Sakaguchi, S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995), 1151–1164.
9. Fontenot, J.D., et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003), 330–336.
10. Hori, S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003), 1057–1061.
11. Arpaia, N., et al. A distinct function of regulatory T cells in tissue protection. Cell 162 (2015), 1078–1089.
12. Feuerer, M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 15 (2009), 930–939.
13. Burzyn, D., et al. A special population of regulatory T cells potentiates muscle repair. Cell 155 (2013), 1282–1295.
14. Laidlaw, B.J., et al. Production of IL-10 by CD4(+) regulatory T cells during the resolution of infection promotes the maturation of memory CD8(+) T cells. Nat. Immunol. 16 (2015), 871–879.
15. Jacobs, J.F.M., et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncol. 13 (2012), E32–E42.
16. Liyanage, U.K., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169 (2002), 2756–2761.
17. Curiel, T.J., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004), 942–949.
18. Shang, B., et al. Prognostic value of tumor-infiltrating FoxP3(+) regulatory T cells in cancers: a systematic review and meta-analysis. Sci. Rep., 5, 2015, 15179.
19. Bates, G.J., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24 (2006), 5373–5380.
20. Tan, W., et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470 (2011), 548–553.
21. Salama, P., et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27 (2009), 186–192.
22. Badoual, C., et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 (2006), 465–472.
23. Grossman, W.J., et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004), 589–601.
24. Strauss, L., et al. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J. Immunol. 182 (2009), 1469–1480.
25. Boyman, O., Sprent, J., The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12 (2012), 180–190.
26. MacIver, N.J., et al. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31 (2013), 259–283.
27. Pandiyan, P., et al. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8 (2007), 1353–1362.
28. Collison, L.W., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450 (2007), 566–569.
29. Steinbrink, K., et al. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159 (1997), 4772–4780.
30. Turnis, M.E., et al. Interleukin-35 limits anti-tumor immunity. Immunity 44 (2016), 316–329.
31. Yamaguchi, Y., et al. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15 (1997), 144–153.
32. Jarnicki, A.G., et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 177 (2006), 896–904.
33. Yu, P., et al. Intratumor depletion of CD4(+) cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005), 779–791.
34. Chen, W., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198 (2003), 1875–1886.
35. Facciabene, A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Immunology, 137, 2012 622–622.
36. Onishi, Y., et al. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10113–10118.
37. Grohmann, U., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3 (2002), 1097–1101.
38. Deaglio, S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204 (2007), 1257–1265.
39. Wilson, J.M., et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol., 182, 2009 4616–4323.
40. Tiemessen, M.M., et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 19446–19451.
41. Hasko, G., Cronstein, B.N., Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 25 (2004), 33–39.
42. Delgoffe, G.M., et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501 (2013), 252–256.
43. Faget, J., et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 71 (2011), 6143–6152.
44. Nizar, S., et al. T regulatory cells, the evolution of targeted immunotherapy. Biochim. Biophys. Acta 1806 (2010), 7–17.
45. Gabrilovich, D., Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004), 941–952.
46. Curti, A., et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25(−) into CD25(+) T regulatory cells. Blood 109 (2007), 2871–2877.
47. Hindley, J.P., et al. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Res. 71 (2011), 736–746.
48. Sainz-Perez, A., et al. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res. 72 (2012), 3557–3569.
49. Malchow, S., et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339 (2013), 1219–1224.
50. Warburg, O., On the origin of cancer cells. Science 123 (1956), 309–314.
51. Ho, P.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
52. Chang, C.H., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
53. Scott, K.E.N., Cleveland, J.L., Lactate wreaks havoc on tumor-infiltrating T and NK cells. Cell Metab. 24 (2016), 649–650.
54. Speiser, D.E., et al. Regulatory circuits of T cell function in cancer. Nat. Rev. Immunol. 16 (2016), 500–611.
55. Michalek, R.D., et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186 (2011), 3299–3303.
56. Fischer, K., et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109 (2007), 3812–3819.
57. Huber, V., et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. Semin. Cancer Biol. 43 (2017), 74–89.
58. Angelin, A., et al. Foxp3 Reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 25 (2017), 1282–1293.
59. Lochner, M., et al. Fatty acid metabolism in the regulation of T cell function. Trends Immunol. 36 (2015), 81–91.
60. Plitas, G., et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45 (2016), 1122–1134.
61. Sinclair, L.V., et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14 (2013), 500–508.
62. Hayashi, K., et al. LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells. J. Immunol. 191 (2013), 4080–4085.
63. Mezrich, J.D., et al. An Interaction between Kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185 (2010), 3190–3198.
64. Fallarino, F., et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176 (2006), 6752–6761.
65. Wainwright, D.A., et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin. Cancer Res. 18 (2012), 6110–6121.
66. Naganuma, M., et al. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177 (2006), 2765–2769.
67. Bao, R., et al. Adenosine promotes Foxp3 expression in Treg cells in sepsis model by activating JNK/AP-1 pathway. Am. J. Transl. Res. 8 (2016), 2284–2292.
68. Nutsch, K., Hsieh, C., When T cells run out of breath: the HIF-1 alpha story. Cell 146 (2011), 673–674.
69. Clambey, E.T., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2784–E2793.
70. Shimizu, J., et al. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999), 5211–5218.
71. Simpson, T.R., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
72. Peggs, K.S., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206 (2009), 1717–1725.
73. Phan, G.Q., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 8372–8377.
74. Paterson, A.M., et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J. Exp. Med. 212 (2015), 1603–1621.
75. Redjimi, N., et al. CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 72 (2012), 4351–4360.
76. Ishida, T., et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 30 (2012), 837–842.
77. Sugiyama, D., et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17945–17950.
78. Muraoka, R.S., et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109 (2002), 1551–1559.
79. Gorelik, L., Flavell, R.A., Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 (2001), 1118–11822.
80. Sun, Z., et al. IL10 and PD-1 cooperate to limit the activity of tumor-specific CD8+ T cells. Cancer Res. 75 (2015), 1635–1644.
81. Vicari, A.P., et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196 (2002), 541–549.
82. Shimizu, J., et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3 (2002), 135–142.
83. Ko, K., et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J. Exp. Med. 202 (2005), 885–891.
84. Cipolletta, D., et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue T-reg cells. Nature 486 (2012), 549–553.
85. D'alessio, F.R., et al. CD4(+)CD25(+)Foxp3(+) Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J. Clin. Invest. 119 (2009), 2898–2913.
86. Samstein, R.M., et al. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 150 (2012), 29–38.
87. Campbell, D.J., Koch, M.A., Phenotypical and functional specialization of FOXP3(+) regulatory T cells. Nat. Rev. Immunol. 11 (2011), 119–130.
88. Liu, G., et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat. Immunol. 10 (2009), 769–777.
89. Jeffery, L.E., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J. Immunol. 183 (2009), 5458–5467.